|Awarded On||May 20, 2015|
|Title||Identifying Inhibitors of Ascl1 to Block Growth of Malignant Neuroendocrine and Neural Tumors|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Jane E Johnson|
|Cancer Sites||Brain and Other Nervous System, Lung and Bronchus|
Tumors with neuroendocrine features arise from a variety of anatomic sites. Because of their diverse tissues of origin, these tumors can have distinct biology. Nevertheless, they can also share properties such as a shared requirement for a specific protein for tumor growth. At least one of these neuroendocrine cancers, small cell lung carcinoma is a focus of the Recalcitrant Cancer Research Act of 2012 because it has a 5-year survival rate of < 20% and is estimated to cause the death of over 30,000 individuals in the US each year. The problem addressed in this proposal is the need for effective treatments for this recalcitrant tumor, and for other tumors with neural and neuroendocrine phenot...